- Home
- TKLF vs RLYB Comparison
TKLF vs RLYB Comparison
Compare TKLF & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- RLYB
- Stock Information
- Founded
- TKLF 2006
- RLYB 2018
- Country
- TKLF Japan
- RLYB United States
- Employees
- TKLF N/A
- RLYB N/A
- Industry
- TKLF Other Specialty Stores
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- RLYB Health Care
- Exchange
- TKLF Nasdaq
- RLYB Nasdaq
- Market Cap
- TKLF 13.3M
- RLYB 13.3M
- IPO Year
- TKLF 2022
- RLYB 2021
- Fundamental
- Price
- TKLF $4.03
- RLYB $0.31
- Analyst Decision
- TKLF
- RLYB Hold
- Analyst Count
- TKLF 0
- RLYB 4
- Target Price
- TKLF N/A
- RLYB $15.00
- AVG Volume (30 Days)
- TKLF 42.3K
- RLYB 81.0K
- Earning Date
- TKLF 12-18-2024
- RLYB 05-08-2025
- Dividend Yield
- TKLF N/A
- RLYB N/A
- EPS Growth
- TKLF N/A
- RLYB N/A
- EPS
- TKLF 1.70
- RLYB N/A
- Revenue
- TKLF $219,520,631.00
- RLYB $848,000.00
- Revenue This Year
- TKLF N/A
- RLYB N/A
- Revenue Next Year
- TKLF N/A
- RLYB N/A
- P/E Ratio
- TKLF $2.37
- RLYB N/A
- Revenue Growth
- TKLF 32.02
- RLYB N/A
- 52 Week Low
- TKLF $2.00
- RLYB $0.22
- 52 Week High
- TKLF $8.53
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- TKLF 76.81
- RLYB 41.01
- Support Level
- TKLF $3.71
- RLYB $0.29
- Resistance Level
- TKLF $3.90
- RLYB $0.32
- Average True Range (ATR)
- TKLF 0.30
- RLYB 0.02
- MACD
- TKLF 0.07
- RLYB 0.01
- Stochastic Oscillator
- TKLF 88.05
- RLYB 48.75
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.